Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Type of study
Language
Publication year range
1.
J Parasitol ; 106(3): 323-333, 2020 06 01.
Article in English | MEDLINE | ID: mdl-32369594

ABSTRACT

Benznidazole and nifurtimox are the only drugs specifically approved for the treatment of Chagas disease. Both compounds are given orally in tablets, but occasionally are ineffective and cause adverse effects. Benznidazole, the first-line treatment in many countries, is a compound with low solubility in water that is administered at high doses for long periods of time. To improve its solubility, we developed a new liquid formulation on the basis of solid dispersions (SD) using the amphiphilic polymer poloxamer 407. Herein we present data on its trypanocidal performance in mouse models of acute and chronic Trypanosoma cruzi infection. SD at doses of 60 or 15 mg/kg per day given with different administration schedules were compared with the commercial formulation (CF; 50 mg/kg per day) and vehicle. The SD performance was assessed by direct parasitemia, total anti-T. cruzi antibodies, and parasitic burden in tissues after 4 or 6 mo posttreatment. The efficacy of the SD was equivalent to the CF but without manifest side effects and hepatotoxicity. Considering our previous data on solubility, together with these on efficacy, this new liquid formulation represents a promising alternative for the treatment of Chagas disease, particularly in cases when dosing poses a challenge, as in infants.


Subject(s)
Chagas Disease/drug therapy , Excipients/therapeutic use , Nitroimidazoles/therapeutic use , Poloxamer/therapeutic use , Trypanocidal Agents/therapeutic use , Acute Disease , Animals , Antibodies, Protozoan/blood , Aspartate Aminotransferases/blood , Chronic Disease , Disease Models, Animal , Female , Heart/parasitology , Mice , Myocardium/pathology , Parasitemia , Quadriceps Muscle/parasitology , Quadriceps Muscle/pathology , Random Allocation , Real-Time Polymerase Chain Reaction , Trypanosoma cruzi/immunology
2.
Infection ; 47(2): 323-329, 2019 Apr.
Article in English | MEDLINE | ID: mdl-30511297

ABSTRACT

Intramuscular cystic echinococcosis is a very rare occurrence. Herein we report a case of a 37-year-old patient who presented with progressive swelling of his left thigh. Ultrasound evaluation showed a multicystic, encapsulated lesion (16 × 3.5 × 8.5 cm) in the M. vastus lateralis, and serology confirmed the diagnosis of Echinococcus granulosus s.l. infection. No additional cysts were detected upon total body CT scan. The patient was treated with albendazole pre-operatively; surgical resection of the mass was then successfully performed. The patient feels well and no signs of residual infestation were seen after 2 years of follow-up.


Subject(s)
Echinococcosis/diagnosis , Echinococcus granulosus/isolation & purification , Quadriceps Muscle/parasitology , Adult , Albendazole/therapeutic use , Animals , Anticestodal Agents/therapeutic use , Austria , Echinococcosis/parasitology , Echinococcosis/pathology , Echinococcosis/surgery , Humans , Male , Quadriceps Muscle/surgery , Thigh/parasitology , Thigh/pathology , Thigh/surgery , Treatment Outcome , Turkey
4.
BMC Infect Dis ; 11: 103, 2011 Apr 21.
Article in English | MEDLINE | ID: mdl-21510859

ABSTRACT

BACKGROUND: Musculoskeletal hydatid cysts are rare, but being locally invasive, can potentially cause significant deformity or pathological fracture. CASE PRESENTATION: A 39 y.o. male presented to our orthopaedic outpatient clinic complaining of severe right hip pain, and inability to ambulate. Symptoms were not preceded by trauma. Subsequent imaging confirmed a large, 17 × 3 × 5 cm echinococcus cyst in the vastus lateralis, causing erosion of the proximal metaphysis of the femur. As a consequence the patient suffered a non-traumatic pathological intertrochanteric femur fracture. The patient was treated with an en-bloc excision of the lesion - the affected soft tissue envelope containing the large cyst - and as a second surgical step a cemented total hip replacement (THR) was implanted under the same anaesthetic. The manuscript reviews the literature regarding musculoskeletal hydatid disease.


Subject(s)
Echinococcosis/complications , Echinococcosis/surgery , Femoral Neck Fractures/surgery , Fractures, Spontaneous/surgery , Quadriceps Muscle/surgery , Adult , Animals , Arthroplasty, Replacement, Hip/statistics & numerical data , Echinococcosis/parasitology , Echinococcosis/pathology , Echinococcus , Femoral Neck Fractures/etiology , Femoral Neck Fractures/parasitology , Fractures, Spontaneous/etiology , Fractures, Spontaneous/parasitology , Hip Fractures/surgery , Humans , Male , Quadriceps Muscle/parasitology , Quadriceps Muscle/pathology
5.
J Orthop Res ; 25(7): 926-32, 2007 Jul.
Article in English | MEDLINE | ID: mdl-17415789

ABSTRACT

Mesenchymal stem cells (MSCs) are immunoprivileged and the allogeneic MSCs implantation has been used to facilitate tissue repairs such as bone and cartilage defect. The present study aimed to investigate the feasibility of xenogeneic MSCs implantation. Green fluorescent protein (GFP) transgenic rat bone marrow-derived MSCs were loaded into HA/TCP Skelite blocks and implanted intramuscularly into the quadriceps of the MF1 and SCID mice. After 11 weeks, the implants were harvested and processed for further examinations. The peripheral blood mononuclear cells of each animal were also collected to measure the in vitro immune responses using mixed lymphocyte culture and cytotoxic assay. In the MF1 mice, some surviving MSCs were found in the explants after 11 weeks of implantation, but there was no sign of new bone formation as neither osteocalcin mRNA nor osteoid tissues were detected in the explants; the lymphocyte proliferation and cytotoxicity against donor MSCs were significantly increased in the animals with the xenogeneic MSCs implantation compared with the control littermates without transplantation. In the control SCID mice, osteoid tissues derived from the implanted MSCs were found in the explants; no difference of lymphocyte proliferation and cytotoxicity against the donor MSCs was detected between the SCID mice with or without MSCs implantation. The data suggested that rat MSCs survived the 11 weeks of xenotransplantation in the MF1 mice, but the increased host immune sensitization led to the impaired in vivo osteogenesis potential of MSCs.


Subject(s)
Bone Marrow Transplantation , Graft Survival/immunology , Mesenchymal Stem Cell Transplantation , Mesenchymal Stem Cells/immunology , Transplantation, Heterologous/immunology , Animals , Animals, Genetically Modified , Cell Proliferation , Cell Survival , Feasibility Studies , Implants, Experimental , Leukocytes, Mononuclear/immunology , Leukocytes, Mononuclear/metabolism , Leukocytes, Mononuclear/pathology , Lymphocyte Culture Test, Mixed , Male , Mesenchymal Stem Cells/metabolism , Mesenchymal Stem Cells/pathology , Mice , Mice, SCID , Osteocalcin/genetics , Osteocalcin/metabolism , Osteogenesis/immunology , Quadriceps Muscle/parasitology , Quadriceps Muscle/surgery , RNA, Messenger/metabolism , Rats , Transplantation, Heterologous/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...